AzTrials
AzTrials

Disc Degenerative DiseasePhase 2/3NCT07187362

Comparison of Posterior Cellular Bonegraft Options for Single Level Lumbar Spinal Fusion

A Phase 2/3 study testing Use iliac bone graft, use bone morphogenetic protein and use bone derived allograft MSCs in people with Disc Degenerative Disease and Spine Fusion for Degenerative Spine Disease, run by Midwest Spine & Brain Institute.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study involves the assessment of alternatives to iliac bone graft during spinal fusion surgery. Four types of bone graft alternatives are being compared to iliac bone graft during the posterior portion of an anterior/posterior one-level lumbar spinal fusion. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
Use iliac bone graft, use bone morphogenetic protein and use bone derived allograft MSCs
Could I receive a placebo?
No, everyone receives an active treatment
How many people
119 participants
Where
No sites listed yet
Study dates
13 Oct 2015to 31 Jan 2020
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Inclusion Criteria: Single level lumbar degenerative disc disease -

Exclusion Criteria: Degenerative spondylolisthesis >grade 1, lytic spondyolisthesis, infection, stenosis requiring laminectomy, cancer, scoliosis, pregnancy

-

About this study

Official title: Comparison of Posterior Cellular Bonegraft Options for Single Level Lumbar Spinal Fusion: A Randomized Trial

This study involves the assessment of alternatives to iliac bone graft during spinal fusion surgery. Four types of bone graft alternatives are being compared to iliac bone graft during the posterior portion of an anterior/posterior one-level lumbar spinal fusion. If you choose to participate in this study, you will be randomized (like a flip of a coin) to receive either your own iliac bone graft, bone morphogenetic protein (BMP, made from proteins found in the human body that stimulate bone growth), or one of the following stem-cell based bone graft alternatives for the posterior portion of your fusion surgery:

  • Orthofix Trinity-made from donor bone and bone marrow stem cells
  • Allosource Allostem-made from donor bone and fat stem cells
  • Nutech Nucel-made from donor bone and placenta (after birth) stem cells
Read more

Each bone graft alternatives has been approved by the United States Food and Drug Administration (FDA) and is commercially available with the exception that BMP application is considered "off-label". That is, BMP it is not approved for this indication, it is currently indicated for anterior fusion. The volume of bone graft that you will receive is the same for each graph type (approximately 5cc). Approximately 150 patients from the Midwest Spine and Brain Institute are expected to be enrolled in this study. If you choose to take part, your participation will last about 2+ year.

At approximately 9 - 15 months after your surgery, you will be asked to return to the Midwest Spine and Brain Institute to undergo a limited CT scan of the fusion level to determine how you are healing. Your pain level and functional ability will also be evaluated at this visit.

Read the detailed description

Consecutive patients who are surgical candidates for a one-level anterior/posterior lumbar fusion are eligible for inclusion into the study. Inclusion criteria included:

  • 18 to 65 years of age.
  • Primary degenerative disc disease of one level with or without prior decompression.
  • None or up to moderate stenosis that could be treated with a laminotomy
  • degenerative spondylolisthesis grade 2 or less.

Exclusion criteria:

  • More than single level symptomatic degenerative disc disease.
  • Advanced stenosis that needed extensive laminectomy for adequate decompression.
  • Lytic spondylolisthesis.

The study proposal underwent IRB review (HealthEast IRB #1510002). All the participants provided written informed consent. After completing IRB approved consent, patients were randomized, by computer generated program, to 5cc IBG or one of 5 other types of PSF osteoinductive bone graft alternatives: bone morphogenic protein (BMP, small Infuse, Medtronic, Memphis, TN), autologous concentrated bone marrow aspirate (BMA) from the iliac crest (combined with 5cc Allo chips), allograft bone marrow derived stem cells (cAlloBone, 5.3cc Trinity Elite, Orthofix, Lewisville, TX), fat derived allograft stem cells (Allostem, AlloSource, Centennial, CO) combined with 5cc morcelized cancellous allograft (cAlloFat), or placental derived allograft stem cells (NuCel, Nutech, Birmingham, Alabama) combined with 5cc morcelized cancellous allograft (cAlloAm). A historical control group of 5cc cancellous freeze-dried allograft (Allo) was used as an inert "negative" control group. There are 27 patients in each group. All anterior fusions used BMP (small Infuse). The decortication technique of the posterior fusion is identical for all patients. All patients have identical fixation instrumentation implanted (anterior lumbar plate and posterior facet screws). Posterior fusions were instrumented to eliminate posterior micromotion and subsequent pseudarthrosis as a confounding variable. All the fusion procedures were performed by the lead author to ensure a uniform surgical technique across all bone graft type groups. Therefore, the surgical technique is as uniform as practically possible to minimize confounding variables related to the surgery with the only variable being the various posterior fusion bone graft materials. Patients are blinded to the posterior type of bone graft. The volume of bone graft is the same for each type, approximately 5cc.

Postoperatively, all patients are followed for a minimum of 2 years. During this time radiographs and lumbar Thin-cut CT scans of the fused level are obtained at approximately one year postoperatively to assess fusion success of both anterior and posterior spinal columns. Specifically for the posterior fusion, if only a unilateral fusion was identified, the fusion was tallied as half fused. The limited (to the levels fused) CT scan had 2.88 mSv radiation exposure, or similar to one year's worth of background radiation. Radiographs at >2 years are reviewed for progressive loss of adjacent segment disc height for assessment of adjacent level degeneration. Secondary endpoints of clinical outcomes are assessed pre- and postoperatively with multiple outcome instruments: visual analog scales (VAS, 0 to 10 scale with greater value is worse pain) for back and leg pain; pain drawing; Oswestry disability index (ODI, 0 to 100 scale with greater value is worse disability); pain medication usage (non-opioid and opioids); and patient self-assessment of procedure success over a minimum 2-year follow-up period. Outcome results are entered by office personnel (blinded to the type of bone graft) into computer spreadsheets, with the treating surgeon blinded to these results. The historical control group consisted of retrospective cohort of consecutive patients which fit the inclusion/exclusion criteria and had their PSF with freeze-dried allograft morcelized bone. Additional surgeries were tracked for all groups, including pseudarthrosis repair, adjacent level decompression, adjacent-level fusion extension, spinal cord stimulator implantation, and posterior instrumentation removal.

Being tested
Use iliac bone graft, use bone morphogenetic protein, use bone derived allograft MSCs, Use adipose tissue derived MSCs, Use amnion/placental derived MSCs
Keywords
surgery, allograft bone
Medical subject headings
Intervertebral Disc Degeneration

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Use iliac bone graftBiological

  • use bone morphogenetic proteinBiological

  • use bone derived allograft MSCsBiological

  • Use adipose tissue derived MSCsBiological

  • Use amnion/placental derived MSCsBiological

Study groups in NCT07187362
Study groupRoleWhat they receive
iliac bone graftActive comparatorold standard of care
Receives: Biological: Use iliac bone graft
Bone morphogenetic proteinExperimentalKnown osteoinductive bone graph
Receives: Biological: use bone morphogenetic protein
MSCs from bone allograftExperimentalextracted MSCs from human cadeveric bone
Receives: Biological: use bone derived allograft MSCs
MSCs from amnion/placental tissueExperimentalMSCs derived from human afterbirth tissue
Receives: Biological: Use amnion/placental derived MSCs
MSCs from human adipose tissueExperimentalMSCs derived from human fat
Receives: Biological: Use adipose tissue derived MSCs

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Solid spinal fusion

    Assessed by thin cut CT scan

    Measured: 1 year

Secondary outcomes (1)
  1. Pain and disability

    Self-assessment questionnaire

    Measured: 1, 2 and 2+ years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Sep 2025
  2. Study start13 Oct 2015
  3. Primary completion2 Aug 2019
  4. Study completion31 Jan 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
randomized, prospective
Masking
Single blind
Who is masked
Participant
Enrolment
119 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07187362
Sponsor's protocol ID
HE 15 10 002
Status last verified
Oct 2025
First submitted
18 Sep 2025
Last updated
8 Oct 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Trial start date began prior to 2017

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Use iliac bone graft, use bone morphogenetic protein and use bone derived allograft MSCs in people with Disc Degenerative Disease and Spine Fusion for Degenerative Spine Disease, run by Midwest Spine & Brain Institute.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Solid spinal fusion (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in